ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0914

RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine

Shailja C. Shah1, Tyler S. Reese2, Laura L. Daniel3, Puran Nepal4, Jacy Zanussi3, Alyson L. Dickson2, Ran Tao2, Adriana M. Hung5, Wei-Qi Wei2, C. Michael Stein2, QiPing Feng2 and Cecilia P. Chung3, 1University of California, San Diego, San Diego, CA, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Miami, Miami, FL, 4Vanderbilt University Medical Center, Vanderbilt, TN, 5Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

Meeting: ACR Convergence 2024

Keywords: Drug toxicity, Genome Wide Association Studies, genomics, Pharmacoepidemiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Pancreatitis is a rare, but potentially life-threatening adverse event associated with the use of azathioprine. Prior studies have found an association between the HLA region and thiopurine-induced acute pancreatitis (TIAP); however, TIAP is generally a diagnosis of exclusion—made only after all other possible causes of pancreatitis have been eliminated.  More recently, drug-associated pancreatic injury has been viewed as a continuum that occurs concurrent with other risk factors for pancreatic injury.

Methods: This was a retrospective study of patients with inflammatory conditions taking azathioprine. We used electronic health records linked to genomic data from two independent cohorts of White patients—BioVU (Vanderbilt’s biobank) for discovery and NIH’s All of Us for replication. We excluded patients who underwent organ transplant. The primary outcome was pancreatic injury defined by amylase or lipase levels greater than twice the upper limit of normal while taking azathioprine. In total, we analyzed ~7.1 million single-nucleotide polymorphisms. We conducted the analyses using Firth logistic regression adjusting for 10 principal components, sex, age, and two azathioprine indication variables (inflammatory bowel disease and all others). All of Us does not permit reporting of exact numbers < 20.

Results: Forty-two patients with pancreatic injury and 2085 control subjects were included from BioVU; the All of Us cohort included < 20 patients with pancreatic injury and 847 control subjects. The GWAS analysis in the BioVU cohort identified an association between pancreatic injury and a SNP at the RAB19 locus (rs2948386, OR=3.47, p=1.46 x 10-8); the association was replicated in the All of Us cohort (OR=2.70, p=4.18 x 10-3).

Conclusion: In summary, we identified rs2948386 at the RAB19 locus as a novel genetic factor for azathioprine-associated pancreatic injury. Previous reports indicate that Rab19 plays a role in autophagy and the severity of pancreatitis in animal models support its potential underlying mechanistic involvement.


Disclosures: S. Shah: None; T. Reese: None; L. Daniel: None; P. Nepal: None; J. Zanussi: None; A. Dickson: None; R. Tao: None; A. Hung: None; W. Wei: None; C. Stein: None; Q. Feng: None; C. Chung: None.

To cite this abstract in AMA style:

Shah S, Reese T, Daniel L, Nepal P, Zanussi J, Dickson A, Tao R, Hung A, Wei W, Stein C, Feng Q, Chung C. RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rab19-and-azathioprine-associated-pancreatic-injury-in-patients-taking-azathioprine/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rab19-and-azathioprine-associated-pancreatic-injury-in-patients-taking-azathioprine/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology